Washington, DC  20549


Quarterly Report Pursuant to Section 13 or 15(d) of the Security Exchange Act of 1934 for the quarterly period ended November 30, 2011


Transmission Report Pursuant to Section 13 or 15(d) of the Security Exchange Act of 1937 for the transition period from ______ to ______

Commission file number:  001-32046

Simulations Plus, Inc.
(Name of registrant as specified in its charter)

(State or other jurisdiction of Incorporation or Organization)
(I.R.S. Employer identification No.)

42505 10th Street West
Lancaster, CA  93534-7059
(Address of principal executive offices including zip code)

(661) 723-7723
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days.Yes [X]  No [_]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes [_]  No [_]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):
[_]  Large accelerated filer
[_]  Accelerated filer
[_]  Non-accelerated filer (Do not check if a smaller reporting company)
[X]   Smaller reporting company
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [_]  No [X]

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of January 13, 2012 was 15,607,895 and no shares of preferred stock were outstanding.

Simulations Plus, Inc.
For the Quarterly Period Ended November 30, 2011

Table of Contents

Item 1.
Financial Statements (Unaudited)
Condensed Balance Sheets at November 30, 2011 (unaudited) and August 31, 2011 (audited)
Condensed Statements of Operations for the three months ended November 30, 2011 and 2010 (unaudited)
Condensed Statements of Cash Flows for the three months ended November 30, 2011 and 2010 (unaudited)
Notes to Condensed Financial Statements (unaudited)
Item 2.
Management’s Discussion and Analysis or Plan of Operations
Results of Operations
Liquidity and Capital Resources
Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Item 4.
Controls and Procedures
Item 1.
Legal Proceedings
Item 1A
Risk Factors
Item 2.
Changes in Securities
Item 3.
Defaults upon Senior Securities
Item 4.
Submission of Matters to a Vote of Security Holders
Item 5.
Other Information
Item 6.

at November 30, 2011 (Unaudited) and August 31, 2011 (Audited)

November 30,
August 31,
Current assets
Cash and cash equivalents
  $ 12,662,240     $ 10,037,891  
Income tax refund receivable
    259,434       259,434  
Accounts receivable, net of allowance for doubtful accounts of $0
    1,203,863       1,170,861  
Contracts receivable
    219,683       185,816  
Prepaid expenses and other current assets
    106,783       123,954  
Deferred income taxes
    134,196       302,076  
Current assets of discontinued operations
    -       1,194,795  
Total current assets
    14,586,199       13,274,827  
Long-term assets
Capitalized computer software development costs, net of accumulated amortization of $4,573,869 and $4,416,669
    2,233,674       2,188,982  
Property and equipment, net (note 3)
    120,491       43,010  
Customer relationships, net of accumulated amortization of $127,169 and $126,172
    873       1,870  
Other assets
    18,445       18,445  
Non-current assets of discontinued operations
    -       340,204  
Total assets
  $ 16,959,682     $ 15,867,338  
Current liabilities
Accounts payable
  $ 314,424     $ 176,136  
Accrued payroll and other expenses
    303,425       276,327  
Accrued bonus to officer
    44,950       -  
Accrued income taxes
    328,900       168,897  
Deferred revenue
    108,482       141,191  
Current liabilities of discontinued operations
    -       378,567  
Total current liabilities
    1,100,181       1,141,118  
Long-term liabilities
Deferred income taxes
    771,726       656,047  
Non-current liabilities of discontinued operations
    -       33,558  
Total liabilities
    1,871,907       1,830,723  
Commitments and contingencies (note 4)
Shareholders' equity (note 5)
Preferred stock, $0.001 par value 10,000,000 shares authorized no shares issued and outstanding
    -       -  
Common stock, $0.001 par value 50,000,000 shares authorized 15,572,943 and 15,572,943 shares issued and outstanding
    4,044       4,044  
Additional paid-in capital
    4,247,789       4,167,650  
Retained earnings
    10,835,942       9,864,921  
Total shareholders' equity
    15,087,775       14,036,615  
Total liabilities and shareholders' equity
  $ 16,959,682     $ 15,867,338  

The accompanying notes are an integral part of these consolidated financial statements.

For the three months ended November 30,

Net sales
  $ 2,247,956     $ 2,050,434  
Cost of sales
    352,370       353,656  
Gross profit
    1,895,586       1,696,778  
Operating expenses
Selling, general, and administrative
    700,113       686,051  
Research and development
    251,935       200,754  
Total operating expenses
    952,048       886,805  
Income from operations
    943,538       809,973  
Other income (expense)
Interest income
    21,873       24,004  
Interest expense
    (3 )     (43 )
Gain on currency exchange
    98,386       -  
Total other income (expense)
    120,256       23,961  
Income from continuing operations before provision for income taxes
    1,063,794       833,934  
Provision for income taxes
    (308,695 )     (257,150 )
Income from continuing operations
    755,099       576,784  
Discontinued operations:
Loss from discontinued operations, net of tax
    (249,898 )     (9,291 )
Gain on sale of Words+, net of tax
    465,820       -  
Results of discontinued operations
    215,922       (9,291 )
Net Income
  $ 971,021     $ 567,493  
Basic earnings per share:
Continuing operations
  $ 0.05     $ 0.04  
Discontinued operations
    0.01       -  
Net basic earnings per share
  $ 0.06     $ 0.04  
Diluted earnings per share
Continuing operations
  $ 0.05     $ 0.03  
Discontinued operations
    0.01       -  
Net diluted earnings per share
  $ 0.06     $ 0.03  
Weighted-average common shares outstanding
    15,572,943       15,691,345  
    16,129,535       16,525,142  
The accompanying notes are an integral part of these consolidated financial statements.

For the three months ended November 30,

Cash flows from operating activities
Net income
  $ 971,021     $ 567,493  
Adjustments to reconcile net income to net cash provided by operating activities
(Income)/Loss from Discontinued Operations
    (215,922 )     9,291  
Depreciation and amortization of property and equipment
    9,037       5,411  
Amortization of customer relationships
    998       2,493  
Amortization of capitalized computer software development costs
    157,200       177,674  
Stock-based compensation
    26,355       45,006  
Deferred income taxes
    250,002       129,789  
(Increase) decrease in
Accounts receivable and Contracts receivable
    (66,869 )     (220,527 )
Income tax refundable
    -       (33,924 )
    -       6  
Prepaid expenses and other assets
    17,171       8,761  
Increase (decrease) in
Accounts payable
    138,287       74,174  
Accrued payroll and other expenses
    19,311       240  
Accrued Bonus
    44,950       43,402  
Accrued income taxes
    160,003       (158,947 )
Deferred revenue
    (32,709 )     (62,922 )
Net cash provided by operating activities of continuing operations
    1,478,835       587,420  
Net cash provided by (used in) operating activities of discontinued operations
    (688,862 )     44,279  
Net cash provided by operating activities
    789,973       631,699  
Cash flows from investing activities
Proceeds from sale of Words+, Inc.
    1,973,096       -  
Purchases of property and equipment
    (86,518 )     -  
Capitalized computer software development costs
    (201,892 )     (158,000 )
Net cash provided by (used in) investing activities of continuing operations
    1,684,686       (158,000 )
Net cash provided by (used in) investing activities of discontinued operations
    6,532       (55,720 )
Net cash provided by (used in) investing activities
    1,691,218       (213,720 )
Cash flows from financing activities
Repurchase of common stock
    -       (1,189,986 )
Proceeds from the exercise of stock options
    -       13,325  
Net cash (used in) financing activities of continuing operations
    -       (1,176,661 )
Net increase (decrease) in cash and cash equivalents from continuing operations
    3,163,521       (747,241 )
Net (decrease) in cash and cash equivalents from discontinued operations
    (682,330 )     (11,441 )
Net increase (decrease) in cash and cash equivalents
    2,481,191       (758,682 )
Cash and cash equivalents, beginning of year
    10,181,049       9,631,762  
Cash and cash equivalents, end of period
  $ 12,662,240     $ 8,873,080  
Supplemental disclosures of cash flow information
Interest paid
  $ 3     $ 118  
Income taxes paid
  $ 170,000     $ 320,232  
The accompanying notes are an integral part of these consolidated financial statements.

Simulations Plus, Inc.

November 30, 2011 and 2010


This report on Form 10-Q for the quarter ended November 30, 2011, should be read in conjunction with the Company's annual report on Form 10-K for the year ended August 31, 2011, filed with the Securities and Exchange Commission (“SEC”) on November 29, 2011. As contemplated by the SEC under Article 8 of Regulation S-X, the accompanying financial statements and footnotes have been condensed and therefore do not contain all disclosures required by generally accepted accounting principles. The interim financial data are unaudited; however, in the opinion of Simulations Plus, Inc. ("we", "our", "us"), the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. Results for interim periods are not necessarily indicative of those to be expected for the full year.

As further discussed in note 9 below, we sold the common stock of our 100% owned subsidiary, Words+, Inc. (“Words+”), as a part of discontinued operations, from September 1, 2011 through November 30, 2011.


Our consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.  Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses.  These estimates and assumptions are affected by management’s application of accounting policies.  Actual results could differ from those estimates.  Significant accounting policies for us include revenue recognition, accounting for capitalized computer software development costs, valuation of stock options, and accounting for income taxes.

Revenue Recognition
We recognize revenues related to software licenses and software maintenance in accordance with the Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) 985-605.  Software product revenue is recorded when the following conditions are met: 1) evidence of arrangement exists, 2) delivery has been made, 3) the amount is fixed, and 4) collectability is probable.  Post-contract customer support ("PCS") obligations are insignificant; therefore, revenue for PCS is recognized at the same time as the licensing fee, and the costs of providing such support services are accrued and amortized over the obligation period.

As a byproduct of ongoing improvements and upgrades for the new programs and new modules of software, some modifications are provided at no additional charge to customers who have already purchased software. Other software modifications result in new, additional-cost modules that expand the functionality of the software. These are licensed separately. We consider the modifications that are provided without charge to be minimal, as they do not significantly change the basic functionality or utility of the software, but rather add convenience, such as being able to plot some additional variable on a graph in addition to the numerous variables that had been available before, or adding some additional calculations to supplement the information provided from running the software. Such software modifications for any single product have typically occurred once or twice per year, sometimes more, sometimes less. Thus, they are infrequent.  The Company provides, for a fee, additional training and service calls to its customers and recognizes revenue at the time the training or service call is provided.

Generally, we enter into one-year license agreements with customers for the use of our pharmaceutical software products.  We recognize revenue on these contracts when all the criteria are met.

Most license agreements have a term of one year; however, from time to time, we enter into multi-year license agreements. We generally unlock and invoice software one year at a time for multi-year licenses. Therefore, revenue is recognized one year at a time.

We recognize the revenue from collaboration research and the revenue from grants equally over their terms.  However, we recognize the contract (consulting) study revenue using the percentage-of-completion method, depending upon how the contract studies are engaged, in accordance with FASB ASC 605-35.  To recognize revenue using the percentage-of-completion method, we must determine whether we meet the following criteria:  1) there is a long-term, legally enforceable contract and 2) it is possible to reasonably estimate the total project costs, and 3) it is possible to reasonably estimate the extent of progress toward completion.

Cash and Cash Equivalents
For purposes of the statements of cash flows, we consider all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Accounts Receivable
We analyze the age of customer balances, historical bad debt experience, customer credit-worthiness, and changes in customer payment terms when making estimates of the collectability of the Company’s trade accounts receivable balances.  If the Company determines that the financial conditions of any of its customers deteriorated, whether due to customer-specific or general economic issues, an increase in the allowance may be made.  Accounts receivable are written off when all collection attempts have failed.  Although we experienced significant collection problems with our former Words+ subsidiary, we have not had customers fail to pay on the pharmaceutical software and services side of the business, which represents our sole line of former subsidiary on November 30, 2011.

Capitalized Computer Software Development Costs
Software development costs are capitalized in accordance with FASB ASC 985-20.  Capitalization of software development costs begins upon the establishment of technological feasibility and is discontinued when the product is available for sale.

The establishment of technological feasibility and the ongoing assessment for recoverability of capitalized software development costs require considerable judgment by management with respect to certain external factors including, but not limited to, technological feasibility, anticipated future gross revenues, estimated economic life, and changes in software and hardware technologies. Capitalized software development costs are comprised primarily of salaries and direct payroll-related costs and the purchase of existing software to be used in our software products.

Amortization of capitalized software development costs is provided on a product-by-product basis on the straight-line method over the estimated economic life of the products (not to exceed five years, although all of our current software products have already been on the market for more than 7 years except for our newest MedChem Designer™ program and we do not foresee an end-of-life for any of them at this point).  Amortization of software development costs amounted to $150,200 and $177,674 for the three months ended November 30, 2011 and 2010, respectively.  We expect future amortization expense to vary due to increases in capitalized computer software development costs.


We test capitalized computer software development costs for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Property and Equipment
Property and equipment are recorded at cost, less accumulated depreciation and amortization.  Depreciation and amortization are provided using the straight-line method over the estimated useful lives as follows:

5 years
Computer equipment
3 to 7 years
Furniture and fixtures
5 to 7 years
Leasehold improvements
Shorter of life of asset or lease

Maintenance and minor replacements are charged to expense as incurred.  Gains and losses on disposals are included in the results of operations.

Fair Value of Financial Instruments
Assets and liabilities recorded at fair value in the Condensed Balance Sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories, as defined by the standard are as follows:

Level Input:
Input Definition:
Level I
Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II
Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III
Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at November 30, 2011 for assets and liabilities measured at fair value on a recurring basis:

Level I
Level II
Level III
Cash and cash equivalents
$  12,662,240
$           -
$           -
$  12,662,240
$  12,662,240
$           -
$           -
$  12,662,240

For certain of our financial instruments, including accounts receivable, accounts payable, accrued payroll and other expenses, accrued bonus to officer, and accrued warranty and service costs, the amounts approximate fair value due to their short maturities.

Research and Development Costs
Research and development costs are charged to expense as incurred until technological feasibility has been established. These costs consist primarily of salaries and direct payroll-related costs.  It also includes purchased software and databases which were developed by other companies and incorporated into, or used in the development of, our final products.


Income Taxes
We utilize FASB ASC 740-10 which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.

Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income.  Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.  The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.

Customer relationships
The Company purchased customer relationships as a part of the acquisition of certain assets of Bioreason, Inc. in November 2005.  Customer relationships was recorded at a cost of $128,042, and is being amortized over 78 months under the sum-of-the-years’-digits method.  Amortization expense for the three months ended November 30, 2011 and 2010 amounted to $998 and $2,493 respectively.  Accumulated amortization as of November 30, 2011 and 2010 was $127,169 and $120,935, respectively.

Earnings per Share
We report earnings per share in accordance with FASB ASC 260-10.  Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of common shares available.  Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.  The components of basic and diluted earnings per share for the three months ended November 30, 2011 and 2010 were as follows:

          Net income attributable to common shareholders
  $ 971,021     $ 567,493  
          Weighted-average number of common shares
outstanding during the 3 months of FY11 and FY10
       15,572,943        15,691,345  
          Dilutive effect of stock options     556,592       833,797  
Common stock and common stock equivalents used for diluted earning per share
    16,129,535       16,525,142  


Stock-Based Compensation
Compensation costs related to stock options are determined in accordance with FASB ASC 718-10 using the modified prospective method.  Under this method, compensation cost includes: (1) compensation cost for all share-based payments granted prior to, but not yet vested as of September 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123 amortized over the options’ vesting period, and (2) compensation cost for all share-based payments granted subsequent to September 1, 2006, based on the grant-date fair value estimated in accordance FASB ASC 718-10, amortized on a straight-line basis over the options’ vesting period.  Stock-based compensation was $80,139 and $45,006 for the three months ended November 30, 2011 and 2010, respectively, and is included in the consolidated statements of operations as Selling, General and Administration (SG&A), and Research and Development expense.  As of November 30, 2011, the unvested options for employees who terminated due to sale of Words+, Inc. are fully vested.  As a result, unamortized portion of such stock-based compensation for those employees was expensed in full at this first fiscal quarter ended as of November 30, 2011.

Concentrations and Uncertainties
International sales accounted for 41% and 34% of net sales for the three months ended November 30, 2011 and 2010, respectively. Four customers accounted for 25%, 10%, 9% (a dealer account in Japan representing various customers), and 8% of net sales during the three months ended November 30, 2011, compared with four customers accounted for 29%, 11%, 10% (a dealer account in Japan representing various customers), and 8% of net sales during the three months ended November 30, 2010.

We operate in the computer software industry, which is highly competitive and changes rapidly.  The Company's operating results could be significantly affected by its ability to develop new products and find new distribution channels for new and existing products.

At November 30, 2011, three customers comprised 21% (a dealer account in Japan representing various customers), 19%, and 8% of its accounts receivable at November 30, 2011, and four customers comprised 25% (a dealer account representing various customers), 23%, 18%, and 10% of accounts receivable at November 30, 2010.

Recently Issued Accounting Pronouncements
In September 2009, the FASB issued ASU 2009-14 which  amends Statement of Position (“SOP”) 97-2, “Software Revenue Recognition”, to exclude tangible products containing software components and non-software components that function together to deliver the product’s essential functionality.  ASU 2009-14 applies to revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, with early application permitted with EITF 08-1.  We adopted this standard in the first quarter of fiscal 2011.  We believe adoption did not have a material effect on the Company’s consolidated financial statements.

In September 2009, the FASB issued ASU 2009-13, “Revenue Arrangements with Multiple Deliverables” (“EITF 08-1”).  ASU 2009-13 amends EITF 00-21, “Revenue Arrangements with Multiple Deliverables”, to require an entity to use an estimated selling price when vendor-specific objective evidence or acceptable third-party evidence does not exist for any products or services included in a multiple element arrangement.  The arrangement consideration should be allocated among the products and services based upon their relative selling prices, thus eliminating the use of the residual method of allocation.  ASU 2009-13 also requires expanded qualitative and quantitative disclosures regarding significant judgments made and changes in applying the guidance.  ASU 2009-13 applies to fiscal years beginning after June 15, 2010, with early application permitted.  We adopted this standard in the first quarter of fiscal 2012.  We believe adoption did not have a material effect on the Company’s consolidated financial statements.



Property and equipment as of November 30, 2011 consisted of the following:

  $ 119,607  
Computer equipment
Furniture and fixtures
Leasehold improvements
     Sub total
Less: Accumulated depreciation and amortization
    (363,186 )
     Net Book Value


Employment Agreement
On July 22, 2011, the Company entered into an employment agreement with its President/Chief Executive Officer that expires in August 2013.  The employment agreement provides for an annual base salary of $300,000 per year, and a performance bonus in an amount not to exceed 10% of Employee’s salary, or $30,000 per year, at the end of each fiscal year.  The specific amount of the bonus to be awarded will be determined by the Compensation Committee of the Board of Directors, based on the financial performance and achievements of the Company for the previous fiscal year.  The agreement also provides Employee stock options, exercisable for five years, to purchase fifty (50) shares of Common Stock for each one thousand dollars ($1,000) of net income before taxes at the end of each fiscal year up to a maximum of 120,000 options over the term of the agreement.  The Company may terminate the agreement upon 30 days' written notice if termination is without cause.  The Company's only obligation would be to pay its President the greater of a) 12 months salary or b) the remainder of the term of the employment agreement from the date of notice of termination.

We are not a party to any litigation at this time and we are not aware of any pending litigation of any kind.



Stock Repurchase
On January 10, 2010, the Board of Directors authorized a renewed share repurchase program (Phase II) effective as of February 15, 2010.  The renewed program enabled the Company to buy back up to one million shares during a 12-month period.

The detail of repurchases made under Phase II is listed in the following table:

Total Number of Shares Purchased
Average Price Paid
per Share
Remaining Shares Authorized for Repurchase Under the Share Repurchase Plan – Phase II
04/01/10 to 04/30/10
    86,976     $ 2.2237       913,024  
05/01/10 to 05/31/10
    170,101     $ 2.3515       742,923  
06/01/10 to 06/30/10
    33,665     $ 2.3670       709,258  
07/01/10 to 07/31/10
    18,789     $ 2.4433       690,469  
08/01/10 to 08/31/10
    10,878     $ 2.4283       679,591  
09/01/10 to 09/30/10
    81,070     $ 2.6969       598,521  
10/01/10 to 10/31/10
    170,494     $ 3.1671       428,027  
11/01/10 to 11/30/10
    146,116     $ 2.9523       281,911  
12/01/10 to 12/31/10
    41,214     $ 2.5716       240,697  
01/01/11 to 01/31/11
    119,469     $ 2.9028       121,228  
02/01/11 to 02/28/11
    117,476     $ 3.4510       3,752  
Phase II Total
    996,248     $ 2.8041          

Stock Option Plan
In September 1996, the Board of Directors adopted, and the shareholders approved, the 1996 Stock Option Plan (the "Option Plan") under which a total of 1,000,000 shares of common stock had been reserved for issuance.  In March 1999, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 2,000,000.  In February 2000, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 4,000,000.  In December 2000, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 5,000,000.  Furthermore, in February 2005, the shareholders approved an additional 1,000,000 shares, resulting in the total number of shares that may be granted under the Option Plan to 6,000,000. The 1996 Stock Option Plan terminated in September 2006 by its term.

On February 23, 2007, the Board of Directors adopted and the shareholders approved the 2007 Stock Option Plan under which a total of 1,000,000 shares of common stock had been reserved for issuance.

Number of Options
Weighted-Average Exercise Price Per Share
Weighted-Average Remaining Contractual Life
Outstanding, August 31, 2011
    957,636     $ 1.40       5.22  
Outstanding, November 30,  2011
    957,636     $ 1.40       4.97  
Exercisable, November 30, 2011
    707,102     $ 1.29       4.31  


The weighted-average remaining contractual life of options outstanding issued under the Plan was 4.97 years at November 30, 2011.  The exercise prices for the options outstanding at November 30, 2011 ranged from $0.26 to $3.27, and the information relating to these options is as follows:

Exercise Price
Awards Outstanding
Awards Exercisable
Weighted Average Remaining Contractual Life
Weighted Average Exercise Price
Weighted Average Remaining Contractual Life
Weighted Average Exercise Price
$ 0.26     $ 1.25       665,636  
4.8 years
  $ 1.02       534,836  
4.1 years
  $ 1.03  
$ 1.26     $ 2.25       150,000  
4.3 years
  $ 1.66       111,066  
4.1 years
  $ 1.65  
$ 2.26     $ 3.27       142,000  
6.6 years
  $ 2.87       61,200  
  6.2 years
  $ 2.97  
5.0 years
  $ 1.40       707,102  
4.3 years
  $ 1.29  

Other Stock Options
As of November 30, 2011, the outside members of the Board of Directors hold options to purchase 79,000 shares of common stock at exercise prices ranging from $0.38 to $6.68, which were granted prior to August 31, 2011.

Transactions in FY12
Number of Options
Weighted-Average Exercise Price Per Share
Outstanding, August 31, 2011
    79,000     $ 1.37  
Outstanding, November 30, 2011
    79,000     $ 1.37  
Exercisable, November 30, 2011
    56,200     $ 1.18  


As of November 30, 2011, included in accrued bonus to officer was $44,950 which represents 5% of the Company's FY12 net income before bonuses and taxes, not exceeding $60,000, paid to the Corporate Secretary, Virginia Woltosz, as an annual bonus as part of the terms of the sale of Words+ to Simulations Plus in 1996.  The last fiscal year’s bonus was paid in August 2011.


We allocate revenues to geographic areas based on the locations of our customers.  Geographical revenues for the three months ended November 30, 2011 and 2010 were as follows (in thousands):

North America
South America
November 30, 2011
  $ 1,313     $ 395     $ 531     $ 10     $ 2,249  
November 30, 2010
    1,250       470       330       -       2,050  

Prior to the sale of Words+ on November 30, 2011, the Company operated in two business segments, which consisted of the pharmaceutical software business and the augmentative communication devise business.  Upon the sale of Words+ on November 30, 2011, the Company ceased operations in the augmentative communication device business.  The results of this segment are presented as discontinued operations in the accompanying financial statements.  The pharmaceutical software segment, which represents the Company’s ongoing business, is presented as continuing operations.


We maintain a 401(K) Plan for all eligible employees, and we make matching contributions equal to 100% of the employee’s elective deferral, not to exceed 4% of total employee compensation.  We can also elect to make a profit-sharing contribution.  Our contributions to this Plan amounted to $19,132 and $17,346 for the three months ended November 30, 2011 and 2010, respectively.




On November 30, 2011, we sold our interest in Words+, Inc. for $1,973,096 in cash.  Words+ operations are now presented as discontinued operations in accordance with accounting rules related to the disposal of long-lived assets.

We recognized a gain of $465,820, net of tax, from this sale, which is included in income from discontinued operations in our condensed statement of operations for the fiscal quarter ended November 30, 2011.  The revenue and expenses of discontinued operations for the first fiscal quarter of 2012 and the fiscal year ended August 31, 2011 are as follows:

(in thousand)
from 09/01/11
to 11/30/11
For the fiscal year ended 08/31/11
Net sales
  $ 479     $ 2,981  
Cost of sales
    265       1,381  
Gross profit
    214       1,600  
Selling, general and administrative
    563       1,466  
Research and development
    55       64  
Total operating expenses
    618       1,530  
Income (Loss) from discontinued operations
    (404 )     70  
Other income
    -       2  
Income (Loss) from discontinued operations before income taxes
    (404 )     72  
(Provision for) income taxes
    154       -  
Results from discontinued operations, net of tax
  $ (250 )   $ 72  

The carrying amount of the assets and liabilities of discontinued operations at August 31, 2011 and just prior to the date of the sale on November 30, 2011 were as follows:

(in thousands)
Cash and cash equivalents
  $ 6     $ 143  
Receivables, net
    357       603  
    392       392  
Prepaid and other current assets
    33       57  
Capitalized software development costs, net
    212       220  
Property and equipment, net
    91       120  
     Total Assets
    1,091       1,535  
Accounts payable
    72       116  
Accrued payroll and other expenses
    109       219  
Accrued warranty and service costs
    37       44  
     Total Liabilities
    218       379  
     Net liabilities of discontinued operations
  $ 873     $ 1,153  


From December 1, 2011 to January 13, 2012, an additional 34,952 shares were issued as results of options exercised.

Item 2. Management's Discussion and Analysis or Plan of Operations

Forward-Looking Statements

This document and the documents incorporated in this document by reference contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact contained in this document and the materials accompanying this document are forward-looking statements.
The forward-looking statements are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. Frequently, but not always, forward-looking statements are identified by the use of the future tense and by words such as “believes,” expects,” “anticipates,” “intends,” “will,” “may,” “could,” “would,” “projects,” “continues,” “estimates” or similar expressions. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those indicated by the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements.
The forward-looking statements contained or incorporated by reference in this document are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”) and are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements include declarations regarding our plans, intentions, beliefs or current expectations.
Among the important factors that could cause actual results to differ materially from those indicated by forward-looking statements are the risks and uncertainties described under “Risk Factors” in our Annual Report and elsewhere in this document and in our other filings with the SEC.
Forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and we do not undertake any obligation to update forward-looking statements to reflect new information, subsequent events or otherwise.



Simulations Plus, Inc., incorporated in 1996, develops and produces software for use in pharmaceutical research and for education, as well as provides contract research services to the pharmaceutical industry.  Simulations Plus also took over responsibility for producing a personal productivity software program called Abbreviate! originally spun out of products for the disabled by its former subsidiary, Words+ for the retail market. Words+, founded in 1981, produces computer software and specialized hardware for use by persons with disabilities. The Words+ subsidiary was sold effective November 30, 2011, and has been treated as “discontinued operations” in the financial statements.  During the first quarter ended November 30, 2011, Words+ continued to refine its products for the disabled and the former subsidiary is now a wholly owned subsidiary of the Prentke Romich Company of Wooster, Ohio. This discussion will therefore focus on the ongoing operations for pharmaceutical software and services and the Abbreviate! utility software.

We currently offer five software products for pharmaceutical research: ADMET Predictor™, MedChem Designer™, MedChem Studio™ (formerly known as ClassPharmer™), DDDPlus™, and GastroPlus™.


ADMET Predictor™
ADMET Predictor is a computer program that takes molecular structures as inputs and predicts over 130 different properties for them at the rate of about 200,000 compounds per hour on a fast personal computer. This capability means that a chemist can screen a very large number of molecules in a very short time using ADMET Predictor. The current state-of-the-art of this type of software allows identifying molecules that are sure to fail as potential drug candidates without the need to synthesize and test them. Millions of “virtual” compounds can now be created and screened in a day, compared to months of work to synthesize and test a few hundred actual compounds. The ability to quickly eliminate obviously poor compounds in this manner enables chemists to investigate a much larger “chemical space” in their search for new medicines.

Pharmaceutical companies spend enormous amounts of money conducting a wide variety of experiments on new molecules each year, resulting in large databases of experimental data. Using this proprietary data to build predictive models provides a second return on their investment; however, model building has traditionally been a tedious activity performed by specialists. The ADMET Modeler program that is integrated into ADMET Predictor enables scientists without model-building experience to use their own experimental data to quickly create high-quality, proprietary predictive models using the same powerful modeling methods we use to build our top-ranked property predictions.

We have been developing Version 6.0 of ADMET Predictor for a number of months, and expect to release it during February 2012. This new version incorporates a powerful and exciting new feature that enables users to generate likely metabolites for any molecule using an embedded version of our MedChem Designer™ program. It also increases the number of predictive models for metabolism and toxicity, and refines many of our earlier predictions, which had already been top-rated in almost every published independent comparison study. In addition, the graphical user interface has been revised and enhanced to make it easier for scientists to find, use, and export the powerful information provided by the program.

MedChem Designer™
MedChem Designer was launched in February 2011. It was at first a molecule drawing program, or “sketcher”, but it has been enhanced to do much more than other molecule drawing programs because of its tight integration with both MedChem Studio and ADMET Predictor. We provide MedChem Designer for free because we believe that in the long run it will help to increase demand for ADMET Predictor and MedChem Studio. Most existing molecule drawing programs are also free, so in order to convince chemists to try MedChem Designer, it must also be provided for free. The free version includes a small set of best-in-class ADMET Predictor property predictions, allowing the chemist to modify molecular structures and then see a few key properties very quickly.

When coupled with a license for ADMET Predictor, MedChem Designer becomes a very powerful de novo design tool for medicinal chemists. With it, they can draw one or more molecular structures, then click on the ADMET Predictor icon and have over 130 properties for each structure calculated in seconds, including our unique ADMET Risk™ index. ADMET Risk provides a single number that tells the chemist how many predicted threshold values were crossed (or violated) by each structure. Thus, in a single number, the chemist can instantly compare how different structural changes affect a large number of predicted properties. As chemists attempt to modify structures to improve one property, they often cause others to become unacceptable. Without ADMET Risk, the chemist has to examine a large number of properties for each new molecule to see if any became unacceptable as a result of changing the structure. Thus, ADMET Risk lets them “see” in many dimensions at once. We believe this provides a novel and unequaled capability for new molecule design. In addition to affecting the therapeutic target, there are many properties that are required for a molecule to become a drug, and ADMET Predictor can predict a large number of such properties if the user has a license for it.


During the first quarter, we extended MedChem Designer’s capabilities to include the ability to show the most likely metabolites that would be produced from a parent molecule. This capability requires licenses for the ADMET Predictor Enslein Metabolism Module and the Metabolite Module. With this capability, the chemist can not only see predicted likely metabolites, but can also use ADMET Predictor to assess whether any of the predicted metabolites would be likely to result in unacceptable adverse effects. It is often the case that a molecule that could have been a good medicine is metabolized into a toxic metabolite that renders the parent molecule dangerous or useless. This ability to predict metabolites and their properties can again reduce the number of molecules that are taken forward into development only to fail at a later stage after considerable time and money have been expended to investigate the molecule and its metabolites. We expect to release MedChem Designer Version 2.0 in February, 2012, with this and other expanded capabilities.

MedChem Studio™
MedChem Studio updates have resulted in an ever-more-powerful tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. MedChem Studio evolved from our acquisition of ClassPharmer™ and ChemTK™ in 2005, which were originally designed to examine the results from high throughput screening experiments of many hundreds to many hundreds of thousands of molecules against a therapeutic target.

For new molecule design, MedChem Designer can be used to refine a small number of molecules; however, going from a very large number of molecules and getting down to a few promising candidate leads is the job of MedChem Studio (with ADMET Predictor).  MedChem Studio has features that enable it to generate very large numbers of molecules using a variety of de novo design methods. Coupled with ADMET Predictor, we believe the two programs provide an unmatched capability for chemists to search through large libraries of compounds that have undergone high throughput screening experiments to find the most promising classes and molecules that are active against a particular target. In addition, MedChem Studio with ADMET Predictor can take an interesting (but not acceptable) molecule and very quickly generate many thousands of high quality analogs (i.e., similar new molecules) using a variety of design algorithms to generate new molecules that are predicted to be both active against the target as well as acceptable in a variety of ADMET properties. MedChem Designer (see above) is also a part of MedChem Studio, so the user can click on the MedChem Designer icon and bring up the drawing window to investigate how further modifications to the structures of molecules generated by MedChem Studio can improve their properties.

Continued enhancement of MedChem Studio has taken place during the first quarter, and the next release is scheduled for February 2012, along with new releases of MedChem Designer and ADMET Predictor.

NCE Project

We believe that the suite of MedChem Studio/MedChem Designer/ADMET Predictor is so powerful that we have initiated our own program of designing and making new molecules (NCEs, or new chemical entities). We have selected as a target the malaria parasite, both because there is a tremendous unmet need for a very low-cost cure, and because external funding opportunities exist if we are successful in generating high-quality lead compounds using our software. As of the end of the first quarter we had completed the design process and we now have molecules of our own design being synthesized by an outside company. Once our contractor has completed the synthesis, we will contract with a laboratory that can test the compounds for activity against the malaria parasite, and if successful, those that show good activity will be sent for additional experiments to measure a few key ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) properties to compare the values vs our ADMET Predictor predictions.

Our goal for this project is not to cure malaria – that would be too much to expect for such a quick project. Rather, our goal is to demonstrate that using our software tools, high-quality lead candidates cen be generated in a fraction of the time and cost usually required to reach that stage of drug development. We expect to pursue additional therapeutic targets in the coming months.


DDDPlus simulates in vitro laboratory experiments used to measure the rate of dissolution of the drug and sometimes the additives (excipients) contained in tablets and capsules under a variety of experimental conditions. This one-of-a-kind software program is used by formulation scientists in industry and the U.S. Food and Drug Administration (FDA) to (1) understand the physical mechanisms affecting dissolution rate for various formulations, (2) reduce the number of cut-and-try attempts to design new drug formulations, and (3) to design in vitro dissolution experiments to better mimic in vivo conditions.

Development during the first quarter was very limited because of priorities on other programs.

Our flagship product and largest source of revenues is GastroPlus. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs administered to humans and animals, and is currently in use at numerous pharmaceutical companies, the U.S. Food and Drug Administration (FDA), the U.S. National Institutes of Health, and other government agencies in the U.S. and other countries.

In addition to every major pharmaceutical company, licenses include government agencies in the U.S and abroad, a growing number of smaller pharmaceutical and biotech companies, generic drug companies, and drug delivery companies (companies that design the tablet or capsule for a drug compound that was developed by another company). Although these companies are smaller than the pharmaceutical giants, we believe they can also save considerable time and money through simulation. We believe this part of the industry, which we believe includes a few thousand companies, represents major continued growth potential for GastroPlus. Our experience has been that the number of new companies adopting GastroPlus continues to grow steadily, adding to the base of annual license renewals each year. Recent consolidations by larger companies have not adversely affected our sales to date. In fact, because of the increased need for improving productivity, those companies have often adopted in silico tools at ever-greater levels, with the result that large company licenses have often increased at renewal time even in the face of such consolidation.

GastroPlus simulations can guide project decisions in various ways. Among the kinds of knowledge gained through such simulations are:
(1) the best estimate for “first dose in human” for a new drug prior to Phase I trials,
(2) whether a potential new drug compound is likely to be absorbed at high enough levels to achieve the desired blood concentrations needed for effective therapy,
(3) whether the absorption process is affected by certain enzymes and transporter proteins in the intestinal tract that may cause the amount of drug reaching the blood to be very different after absorption from one region of the intestine to another,
(4) when certain properties of a new compound are probably adequately estimated by in silico predictions (such as from ADMET Predictor) or from simple experiments, rather than through more expensive and time-consuming in vitro or animal experiments,
(5) what the likely variations in blood and tissue concentration levels of a new drug would be in a large population, in different age groups or in different ethnic groups, and
(6) whether a new formulation for an existing approved drug is likely to demonstrate “bioequivalence” (equivalent blood concentration versus time) to the currently marketed dosage form in a human trial (important for generic drug companies and the Office of Generic Drugs at the FDA, which has numerous licenses for GastroPlus).

First quarter efforts on GastroPlus have been focused on the release of Version 8.0, scheduled for February 2012. This new version will
extend the predictive capabilities for ocular and nasal/pulmonary dosing,
adding a paracellular permeability capability that distinguishes between how drug molecules permeate the intestinal membrane by moving between the epithelial cells from the diffusion through the cells,
enhancing the PDPlus™ pharmacodynamic module to incorporate a tumor compartment model and to better deal with multiple metabolites,
provide enhanced graphical outputs and reporting capabilities requested by customers.


Contract Research and Consulting Services
Our recognized world-class expertise in oral absorption and pharmacokinetics is evidenced by the fact that our staff members have been speakers or presenters at over 50 prestigious scientific meetings worldwide in the past five years. We frequently conduct contracted studies for large customers (including top 5 pharmaceutical companies) who have particularly difficult problems and who recognize our expertise in solving them, as well as for smaller customers who prefer to have studies run by our scientists rather than to license our software and train someone to use it. The demand for our consulting services has been increasing steadily, and we expect this trend to continue. Long-term collaborations and shorter-term consulting contracts serve both to showcase our technologies and to build and strengthen customer relationships.

During the first quarter we continued our work on our 5-year collaboration agreement with the Center for Food Safety and Applied Nutrition (CFSAN) of the U.S. Food and Drug Administration (FDA) using ADMET Predictor/Modeler to build predictive models for likely toxicities of food additives and contaminants. We’ve analyzed FDA databases and worked with FDA scientists to ensure that the FDA data to be used for building new predictive models is as correct as we can reasonable make it. We’ve begun building a series of models to classify new compounds as carcinogenic (cancer-causing) in rats and/or mice from large FDA datasets. Included in this effort was a special modification to ADMET Predictor to allow the user to set a minimum value for specificity or sensitivity when building a model. Sensitivity refers to how well a model identifies toxic (or any other property) compounds. A model that said all compounds are toxic would have 100% sensitivity, because all toxic compounds would be labeled as such; however, all nontoxic compounds would also be labeled toxic. Specificity refers to how well a model distinguishes between toxic and nontoxic compounds. Increasing one almost always results in decreasing the other. Depending on the purpose of the model, some scientists will prefer to train models that emphasize one statistic over the other.


Our business strategy is to do the things we need to do to promote growth both organically (by expanding our current products and services through in-house efforts) and by acquisition. We believe that the fundamental science and technology that underlies our business units are the keys to improving our existing products and to expanding the product line with new products that meet our various customers’ needs. The search for suitable acquisitions continues to be a high priority. During the first quarter, we concluded our attempted acquisition of the assets of Entelos in Bankruptcy Court.  Unfortunately, we were not successful in this acquisition. Although early indications were that this acquisition could be accomplished for somewhere in the range of two million dollars, when we attended the final auction at the court in Delaware, we learned that the first secured creditor was prepared to bid up to over ten million dollars (since no cash was required on their part to do so). We were not willing to use virtually all of our cash for this acquisition.

We evaluated software from another potential acquisition during the first quarter, but the quality of the predictions and ease-of-use were far short of the quality we provide, and the investment in time and money that would be required to bring it up to Simulations Plus standards would have resulted in a major adverse impact on our operations and financial performance. With our constantly growing cash reserves, we continue to seek suitable acquisitions, as well as to consider other uses of cash, including another share repurchase program and/or ongoing cash dividends at a level that would be less than current free cash flow, so that cash would continue to grow. No assurances can be provided that either a share repurchase program or a dividend of any kind will be instituted.

Discontinued Operations

On November 30, 2011 we sold our entire interest in our 100% owned subsidiary, Words+, an augmentative and alternative communication device manufacturer for aggregate gross proceeds of $1.97 million.  We recognized a gain of approximately $465,820 from the sale of Words+, which is included in discontinued operations in our statement of operations for the fiscal quarter ended November 30, 2011.  The difference between the sales price and the net gain is a result of adjustments to net working capital from August 31, 2011 until the closing on November 30, 2011, legal fees, auditing fees, tax specialist’s fees, and severance compensation for terminated employees.


Results of Operations

Comparison of Three Months Ended November 30, 2011 and 2010.

The following table sets forth our consolidated statements of operations (in thousands) and the percentages that such items bear to net sales:

Three Months Ended
Net sales
  $ 2,248       100 %   $ 2,050       100 %
Cost of sales
    352       15.7       353       17.2  
Gross profit
    1,896       84.3       1,697       82.8  
Selling, general and administrative
    700       31.1       686       33.5  
Research and development
    252       11.2       201       9.8  
Total operating expenses
    952       42.4       887       43.3  
Income from continuing operations
    944       42.0       810       39.5  
Other income
    120       5.3       24       1.2  
Income from continuing operations before taxes
    1,064       47.3       834       40.7  
(Provision for) income taxes
    (309 )     (13.7 )     (257 )     (12.5 )
Income from continuing operations
    755       33.6       577       28.1  
Loss from discontinued operations, net
    (250 )     (11.1 )     (9 )     (0.4 )
Gain on disposal of discontinued operations, net
    466       20.7       -       -  
Results of discontinued operations
    216       9.6       (9 )     (0.4 )
Net income
  $ 971       43.2 %   $ 568       27.7 %

Net Sales
Net sales increased $198,000, or 9.6%, to $2,248,000 in the first fiscal quarter of Fiscal Year 2012 (“1QFY12”) from $2,050,000 in the first fiscal quarter of Fiscal Year 2011 (“1QFY11)”.  We attribute the increase in revenues due to an approximately $261,000 increase in software licenses from new customers as well as orders for additional licenses from existing customers.  In 1QFY11, we had grant revenue of approximately $67,000 while no such revenue was received in 1QFY12; however the decrease in grant revenue did not affect the total revenue because the increase in revenue from software licenses outweighed the decreases in revenue from grants.

Cost of Sales
Cost of sales was almost the same with a decrease of $1,000, or 0.4%, to $352,000 in 1QFY12 from $353,000 in 1QFY11, however, as a percentage of revenue, it decreased from 17.2% in 1QFY11 to 15.7%.  A significant portion of cost of sales for pharmaceutical software products is the systematic amortization of capitalized software development costs, which is an independent fixed cost rather than a variable cost related to sales.  This amortization cost decreased approximately $20,000, or 12%, in 1QFY12 compared with 1QFY11.  Royalty expense, another significant portion of cost of sales, increased approximately $16,000, or 14%, in 1QFY12 compared with 1QFY11.  We pay a royalty on the core GastroPlus software licenses but not on its optional modules.  We also pay royalties on the Enslein Metabolism Module in our ADMET Predictor software to Enslein Research, Inc. and on the Metabolite module in our ADMET Predictor software to Accelrys (formerly to Symyx, which was acquired by Accelrys).  The cost of sales for contract studies, tech support, and training which consists mainly of salaries for scientists, increased approximately $3,000 due to increases in salaries for existing employees.

Gross Profit
Gross profit increased $199,000, or 11.7%, to $1,896,000 in 1QFY12 from $1,697,000 in 1QFY11.  We attribute this increase to the increased revenue while maintaining cost of sales at a similar level.


Selling, General and Administrative Expenses
Consolidated selling, general and administrative (SG&A) expenses increased $14,000, or 2.0%, to $700,000 in 1QFY12 from $686,000 in 1QFY11, however, as a percent of sales, SG&A decreased to 31.1% from 33.5% in 1QFY11.  The major increases in SG&A expense were legal fees of approximately $54,000 which were incurred related to our attempt to acquire certain assets of Entelos in bankruptcy court.  The remaining increase of $2,000 was due to increases in marketing and sales expenses for trade shows, and advertising, R&D personnel spending more hours in sales activities, rent increase, and insurance and payroll taxes, which outweighed decreases in investor relations and equipment rental.
Research and Development
We incurred approximately $454,000 of research and development costs during 1QFY12.  Of this amount, $202,000 was capitalized and $252,000 was expensed.  In 1QFY11, we incurred $395,000 of research and development costs, of which $187,000 was capitalized and $208,000 was expensed.  The increase of $59,000, or 15%, in total research and development expenditures from 1QFY11 to 1QFY12 was due to the expansion of staff and increases in salaries for existing employees.

Other income (expense)
Net other income in 1QFY12 increased by $96,000, or 400%, to $120,000 in 1QFY12 from $24,000 in 1QFY11.  This is due to the fact that we invoiced in US dollar currency rather than Japanese yen in 1QFY11 in accordance with our Japanese distributor’s request, resulting in no gain on currency exchange in 1QFY11.
Provision for Income Taxes
The provision for income taxes increased by $52,000 or 20.0%, to $309,000 in 1QFY12 from $257,000 in 1QFY11 due to increased net income.  Our tax rate decreased to 29% in 1QFY12 from 31% in 1QFY11.

Income from Continuing Operations
Net income from continuing operations increased by $178,000, or 30.9%, to $755,000 in 1QFY12 from $577,000 in 1QFY11.  We attribute this increase to an increase in gross profit which outweighed an increase in expenses which included approximately $54,000 one-time charges for expenses incurred on our attempt to purchase of Entelos.

Liquidity and Capital Resources

Our principal sources of capital have been cash flows from our operations.  We have achieved continuous positive operating cash flow over the last eight fiscal years.  We believe that our existing capital and anticipated funds from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the foreseeable future.  Thereafter, if cash generated from operations is insufficient to satisfy our capital requirements, we may open a revolving line of credit with a bank, or we may have to sell additional equity or debt securities or obtain expanded credit facilities.  In the event such financing is needed in the future, there can be no assurance that such financing will be available to us, or, if available, that it will be in amounts and on terms acceptable to us. If cash flows from operations became insufficient to continue operations at the current level, and if no additional financing was obtained, then management would restructure the Company in a way to preserve its pharmaceutical business while maintaining expenses within operating cash flows.

Item 3. Quantitative and Qualitative Disclosures about Market Risk
Our risk from exposure to financial markets is limited to foreign exchange variances and fluctuations in interest rates. We may be subject to some foreign exchange risks.  Most of our business transactions are in U.S. dollars, although we generate significant revenues from customers overseas.  The exception is that we have been compensated in Japanese yen by some Japanese customers and in Euros by one European customer; however during 1QFY11, our business transactions were all in U.S. dollars by customers’ requests.  As a result, we experienced no gain in 1QFY11 while we had a gain in 1QFY12.  In the future, if foreign currency transactions increase significantly, then we may mitigate this effect through foreign currency forward contracts whose market-to-market gains or losses are recorded in "Other Income or expense" at the time of the transaction.  To date, exchange rate exposure has not resulted in a material impact.


Item 4. Controls and Procedures
We are responsible for maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.  In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on management’s evaluation (with the participation of our chief executive officer and chief financial officer) of our disclosure controls and procedures as required by Rule 13a-15 under the Exchange Act, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective.

Management's Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal controls over financial reporting, as defined in Exchange Act Rule 13a-15(f). Our internal controls over financial reporting are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles.

No changes were made in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during our most recent fiscal quarter that have materially affected or are reasonably likely to materially affect, our internal controls over financial reporting.

Our management, including our CEO and CFO, does not expect that our disclosure controls or internal controls over financial reporting will prevent all errors or all instances of fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitation of a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Part II.  Other Information

Item 1. 
Legal Proceedings

The Company is not a party to any legal proceedings and is not aware of any pending legal proceedings of any kind.

Item 2. 
Changes in Securities

Item 3. 
Defaults Upon Senior Securities

Item 4. 
Submission of Matters to a Vote of Security Holders

Item 5. 
Other Information

Item 6. 

NUMBER                                           DESCRIPTION
Articles of Incorporation of Simulations Plus, Inc. (7)
Amended and Restated Bylaws of Simulations Plus, Inc. (7)
Articles of Incorporation of Simulations Plus, Inc. (incorporated by reference to Exhibit 3.1 hereof) and Bylaws of Simulations Plus, Inc. (incorporated by reference to Exhibit 3.2 hereof)
Form of Common Stock Certificate (1)
Share Exchange Agreement (1)
Simulations Plus, Inc. 1996 Stock Option Plan (the “Option Plan”) and forms of agreements relating thereto (1) (†)
Exclusive Software License Agreement by and between Simulations Plus, Inc. and Therapeutic Systems Research Laboratories dated June 30, 1997. (2)
OEM/Remarketing Agreement between Words+, Inc. and Eloquent Technology, Inc. (6)
Technology Transfer Agreement between Sam Communications, LLC. (6)
Lease Agreement by and between Simulations Plus, Inc. and Venture Freeway, LLC. (3)
Simulations Plus, Inc. 2007 Stock Option Plan (the “2007 Option Plan”) (5) (†)
Lease extension agreement by and between Simulations Plus, Inc. and Crest Development (7)
Employment Agreement by and between the Company and Walter S. Woltosz (8) (†)
Bill of Sale by and between Simulations Plus, Inc. and Entelos, Inc. dated September 19, 2011 (9)
Stock Purchase Agreement by and among Simulations Plus, Inc., Words+, Inc., and Prentke Romich Company dated November 15, 2011 (10)
Rule 13a-14(a)/15d-14(a) – Certification of Chief Executive Officer (CEO). (11)
Rule 13a-14(a)/15d-14(a) – Certification of Chief Financial Officer (CFO). (11)
Section 1350 – Certification of CEO and CFO. (11)
XBRL Instance Document (11)
XBRL Schema Document (11)
XBRL Calculation Linkbase Document (11)
XBRL Definition Linkbase Document (11)
XBRL Label Linkbase Document (11)
XBRL Presentation Linkbase Document (11)
Incorporated by reference to the Company’s Registration Statement on Form SB-2 (Registration No. 333-6680) filed on March 25, 1997.
Incorporated by reference to the Company’s Form 10-KSB filed December 15, 1997 (Commission file No. 333-05400-LA).
Incorporated by reference to the Company’s Form 10-KSB filed December 15, 1997 (Commission file No. 333-05400-LA).
 Incorporated by reference to the Company’s Form 10-K filed November 30, 2010 (Commission file No. 001-32046).
Incorporated by reference to the Company’s Form 10-Q filed January 13, 2010 (Commission No. 001-32046)
Incorporated by reference to the Company’s Form 10-K/A filed on March 1, 2010 (Commission file No. 001-32046).
Incorporated by reference to the Company’s Form 10-K filed November 29, 2010 (Commission No. 001-32046)
Incorporated by reference to the Company’s Form 10-K filed November 29, 2011 (Commission No. 001-32046)
Incorporated by reference to the Company’s Form 8-K filed September 22, 2011 (Commission No. 001-32046)
Incorporated by reference to the Company’s Form 8-K filed November 16, 2011 (Commission No. 001-32046)
 Filed herewith


In accordance with Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lancaster, State of California, on January 17, 2012.
  Simulations Plus, Inc.  
Date: January 17, 2012
    Momoko Beran  
    Chief Financial Officer